Biomunex Pharmaceuticals
96bis Boulevard Raspail
Paris
75006
France
Website: http://www.biomunex.com/
Email: contact@biomunex.com
About Biomunex Pharmaceuticals
Biomunex is a biopharmaceutical company focused on the discovery and development of innovative bispecific antibody therapeutics, based on a proprietary platform, to address unmet medical needs in the treatment of cancer.YEAR FOUNDED:
2014
LEADERSHIP:
Founder and CEO: Dr. Pierre-Emmanuel Gerard
CSO: Dr. Eugene Zhukovsky
CAREER:
Please click here for Biomunex's job opportunities.
TECHNOLOGY & Products:
Please click here for Biomunex's technology.
4 articles with Biomunex Pharmaceuticals
-
Onward Therapeutics and Biomunex Pharmaceuticals Enter into a Worldwide Exclusive License and Co-development Agreement to a Bispecific Antibody for Immuno-Oncology
2/16/2021
Onward Therapeutics SA announced the execution of a worldwide exclusive license and co-development agreement with Biomunex Pharmaceuticals SAS, Paris, France, of a bispecific antibody targeting two immune checkpoints.
-
Biomunex Pharmaceuticals Establishes US Subsidiary
5/28/2019
Biomunex Inc. to focus on R&D and business development activities in the US
-
Biomunex Pharmaceuticals signs a licensing agreement with Sanofi for the development of bi- and multi-specific antibodies
1/15/2019
Under the terms of the agreement, Sanofi will have access to Biomunex' proprietary technology to generate and optimize bi- and multi-specific antibody therapeutics.
-
Biomunex Appoints Dr. Sebastian Amigorena And Dr. Dragan Grabulovski As Key Scientific And Strategic Advisors
12/5/2016